PDB62 Cost-Effectiveness Modelling of Type-1 Diabetes  by Thokala, P. et al.
glutide than with sitagliptin based on data from a recently published 52-week
clinical trial.
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COST-EFFECTIVENESS OF ADDING A PHARMACIST TO THE PRIMARY CARE
TEAM FOR THE MANAGEMENT OF TYPE 2 DIABETES PATIENTS
Yu J1, Shah B1, Ip EJ1, Chan J2
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OBJECTIVES: To evaluate the cost effectiveness of pharmacist intervention (the
enhanced care group-ECG) relative to primary care physicians only (control group)
in improving cardiovascular (CVD) outcomes among patients with Type 2 diabetes
mellitus (T2DM). METHODS: Data were collected from medical charts at Kaiser
Permanente (KP) clinics. Patients in the ECG were matched 1:1 to patients in the
control group based on age, gender, HbA1C, and Charlson comorbidity score. The
UKPDS risk engine was used to estimate the 10-year CVD risk. A Markov state-
transitionmodel was developed to simulate the difference in CVD risk between the
two hypothetical cohorts of ECG and control group. The primary outcome was the
incremental cost and effectivenessmeasured by life years and per quality-adjusted
life year (QALY) gained. Sensitivity analysis(SA) was conducted to examine the
robustness of the results. RESULTS: The base case model suggests that the ECG
dominated the control group with lower treatment cost ($35,740 vs. $44,528) per
patient and more life years (8.9 vs.8.1) and QALY (5.51 vs. 5.02) over the 10-year
period. Within the reasonable range of variability of all parameters, however, the
multiple one-way SA revealed that the relative value of ECG depends on the time
horizon adopted by the payers. The probabilistic sensitivity analysis suggests that
when adopting a longer time horizon such as 5 or more years in management, the
ECG has a far higher chance of being chosen as a cost-effective strategy regardless
of the level of willingness to pay. When the time horizon was shortened, however,
the likelihood for the ECG being cost- effective decreased. CONCLUSIONS: Adding
pharmacists to the health care management team for diabetic patients can be a
cost-effective strategy in terms of the improvements in the cardiovascular out-
come achieved over the long term.
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COST-EFFECTIVENESS ANALYSES OF TYPE 2 DIABETES MELLITUS
TREATMENTS PUBLISHED IN THE UNITED STATES: A SYSTEMATIC
LITERATURE REVIEW OF RESULTS AND QUALITY ASSESSMENT
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OBJECTIVES: 1) To identify key features of cost-effectiveness analyses (CEAs) of
type 2 diabetes mellitus (T2DM) of the United States (US) population; 2) to assess
the quality of T2DM CEAs; and 3) to identify the predictors of quality. METHODS:
We searched PubMed for several MeSH terms with English language restriction,
through August 2011. The quality of eligible studies was evaluated using the Qual-
ity of Health Economic Evaluation (QHES) instrument. Multiple linear regression
analysis was conducted for the predictors of quality (overall QHES score) and inde-
pendent variables being features of the T2DMCEA literature.RESULTS:A total of 38
full-text articles met inclusion criteria of which: Forty-six percent were pharma-
ceutical companies funded/sponsored, 82% were conducted from healthcare pay-
ers perspective, 77%were published in clinical-focused journals, 85% used quality-
adjusted life-years (QALYs), 79% used published literature as the data source, 28%
used the Center for Outcomes Research diabetes model, 51% were classified as
disease treatment/management, and 64% used more than one-way sensitivity
analysis. Overall, mean quality score using QHES was 73.211.5 and only 51% of
studies scored75 (high-quality). Many studies (69%) failed to describe the analysis
perspective and/or reasons for its selection; whereas, most of the studies (95%)
used valid and reliable health outcomes scales/measures. Multiple linear regres-
sion found the following significant variables (p0.05): journal impact factor
(11.2, CI7.4-14.0), studies using QALY (34.9, CI11.2-48.1), and published
after year 2000 (35.8, CI13.9-48.6). CONCLUSIONS: All studies funded/spon-
sored by a pharmaceutical company concluded the product of that company to be
cost-effective; thismay be indicative of publication bias and/or design bias. Several
studies failed to follow the societal perspective recommendations of the US Panel
on Cost-effectiveness in Health and Medicine, possibly because of preferences of
the funding agency or researcher’s interests. Decisions based on these studies
should consider quality and other key features of the later.
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COST-EFFECTIVENESS ANALYSIS OF MEDICATION THERAPY MANAGEMENT IN
PATIENTS WITH TYPE 2 DIABETES IN COMMUNITY PHARMACY/AMBULATORY
CARE SETTINGS: RESULTS FROM A DECISION-ANALYTIC MARKOV MODEL
Hussein M, Brown LM
University of Tennessee Health Science Center, Memphis, TN, USA
OBJECTIVES: Pharmacist-provided medication therapy management (MTM) has
been reported to improve patient outcomes in a variety of settings and patient
populations. Yet, little is known about the long-term economic and clinical out-
comes of MTM. Here, we sought to estimate the incremental, lifetime cost-effec-
tiveness of MTM in type 2 diabetes, over usual dispensing care, from a health
payer perspective. METHODS: We constructed a decision-analytic Markov model
with 10 diabetes disease states. A hypothetical cohort of 40-year-old patients were
followed for the rest of their life expectancy (31 years). Transition probabilities
were derived from the validated CDC-RTI diabetes model. Costs (in 2010 dollars)
associated with each disease state were derived from the ADA’s 2007 report on
diabetes costs. In the base case, MTMwas assumed to increase annual, per-patient
direct medical costs by 1.7%, which is a median of values retrieved from the liter-
ature. Glycemic levels reported under MTMwere used to model the corresponding
effects on the risks for microvascular complications via an exponential parametric
form (Eastman 1997). Risk reduction for coronary heart disease under MTM was
taken from the Fremantle Diabetes Trial. The primary outcome of the model is the
incremental cost per quality-adjusted life-years (QALYs) gained. Future costs and
QALYs were discounted at 3% per annum. Sensitivity analyses were undertaken to
assess model robustness and uncertainties. RESULTS: Over usual care, MTMwas
estimated to result in an additional 0.44 QALYs, and in lifetime cost savings of
approximately $20,000 per patient. MTM appeared to improve survival by 4%. Our
estimates are robust to plausible variations in key parameters, and are most sen-
sitive to the probability of nephropathy, and to the effect of MTM on costs.
CONCLUSIONS: Our results suggest that MTM dominates usual care. The increase
in direct medical costs associated with MTM appears to be offset by large cost
savings due to reduction in diabetes-related morbidity and mortality.
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A COST-UTILITY ANALYSIS OF PREGABALIN VERSUS DULOXETINE IN PAINFUL
DIABETIC NEUROPATHY
Bellows BK, Dahal A, Jiao T, Biskupiak J
University of Utah, Salt Lake City, UT, USA
OBJECTIVES: To determine the cost-utility of pregabalin (PRE) vs. duloxetine (DUL)
over a 6 month time horizon from the perspective of US third-party payers using a
decision tree analysis.METHODS: Literature searches identified clinical trials and
real-world studies reporting the efficacy, tolerability, safety, adherence, opioid us-
age, and healthcare utilization and costs of PRE and DUL. The proportions of pa-
tients reported in the included studies were used to determine probabilities in the
decision tree model. Average wholesale price was used to determine the costs of
medications. The costs associated with healthcare utilization were determined
from observational studies and all costs were adjusted to 2011 US dollars. Utility
values formoderate to severe andmild painwere determined fromEuroQoL scores.
The overall utility values were determined by multiplying the utility values by the
disutility values associatedwith adverse events. The base-casemodel included the
FDA approved doses of PRE (300 mg/day) and DUL (60 mg/day) while “real-world”
sensitivity analyses explored the effects over a range of doses (PRE 75-600 mg/day,
DUL 20-120 mg/day). Monte Carlo simulations with 1000 repetitions were used to
perform probabilistic sensitivity analyses (PSA) to examine uncertainty of the es-
timates used in the model. Outcomes from the model were expressed as cost per
quality adjusted life-year (QALY). RESULTS: In the base-case model DUL cost less
and was more effective than PRE (incremental cost -$187, incremental effective-
ness 0.011 QALYs). Results from the real-world sensitivity analyses indicated that
DUL was $16,000 and $20,667 more per QALY than PRE. Cost-effectiveness accept-
ability curves showed that DUL has a higher probability of being cost-effective,
except at very lowwillingness-to-pay thresholds. CONCLUSIONS:Using a decision
tree model that incorporated both clinical trial and real-world data, DUL was a
more cost-effective option than PRE in the treatment of PDN from the perspective
of third-party payers.
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THE BURDEN OF DIABETES MELLITUS FOR MEDICARE BENEFICIARIES
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OBJECTIVES: To estimate health care costs and utilization for Medicare beneficia-
ries with type 1 or type 2 diabetes and matched control cohorts. METHODS: We
used a retrospective claims cohort analysis to assess the direct healthcare cost and
utilization of health services in 2009 for patients aged 65 to 89 enrolled in a Medi-
care Advantage plus prescription drug plan. Patients were matched 1:1 with non-
diabetes patients. All-cause health care costs for 2009were calculated as the sumof
all medical and pharmacy claims, and costs directly attributable to diabetes were
evaluated for case cohorts. RESULTS: Our analysis included 6,562 type 1 cases and
the same number of matched controls, and 194,775 type 2 cases and their matched
controls. There were no significant demographic differences between cohorts for
matched variables. Type 2 cases had significantly higher mean Deyo-Charlson Co-
morbidity Index compared to controls (2.47 versus 0.77; p.001), although all
groups had high prevalence of expensive comorbidities such as hypertension
and heart disease. Mean all-cause healthcare costs per patient per year were
significantly higher for type 1 and type 2 cases versus controls for in-patient
hospitalization, outpatient, office, ER visits, pharmacy and total health care
costs (total 2009 costs: type 1 $20,701$30,201, type 1 controls $6,537$10,441,
type 2 $10,437$18,518, type 2 controls $6,505$11,140). The mean diabetes
attributable total health care cost for type 1 and type 2 cohorts were $9,443 
$15,665 and $3,616  $9,229, respectively, per patient per year. CONCLUSIONS:
Diabetes escalates health care costs for Medicare Advantage patients in compari-
son to those without the disease regardless of comorbidities.
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COST-EFFECTIVENESS MODELLING OF TYPE-1 DIABETES
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OBJECTIVES: To build a flexible and comprehensive long term Type-1 diabetes
model incorporating themost up-to-date methodologies (e.g. capturing parameter
uncertainty, timeprofile of patient characteristics and including patient behaviour)
to allow a number of cost-effectiveness evaluations.METHODS: An individual pa-
tient level discrete event simulationmodel which includes all the major complica-
tions (nephropathy, neuropathy, retinopathy, CVD, PVD, hypoglycaemia, ketoaci-
dosis) and their interactions along with the treatment effects was built based on
the developed conceptual model. Patient characteristics (demographics, clinical
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variables, existing complications and treatment status) are used to estimate the
transition probabilities for different eventswithHbA1c acting as the key variable in
themodel. Patient behaviourwas also incorporated in the cost-effectivenessmodel
by updating HbA1c and other variables in time based on the patient’s behaviour.
Furthermore, the model is capable of performing probabilistic sensitivity analysis
allowing us to capture the effects of parameter uncertainty and report the likeli-
hood that interventions are cost-effective. RESULTS: A number of cost-effective
analyses were performed and the trade-offs between costs and QALYs are pre-
sented for different treatment/interventions. Screening strategies were also eval-
uated by comparing the cost savings and improvements in life expectancy.
CONCLUSIONS: The flexible individual patient level discrete event simulation
model developed enables cost-effectiveness evaluations of a number of treatments
and interventions for Type-1 diabetes. The model allows tracking the history of
each of the patients and this enables identification of different sub-groups for
targeted interventions.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes & Patient
Preference Studies
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COMPARING MEDICATION ADHERENCE, PERSISTENCE AND DISCONTINUATION
RATES TO PREGABALIN AND DULOXETINE AMONG TYPE 2 DIABETIC PATIENTS
Oladapo AO, Adeyemi A, Barner JC
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OBJECTIVES: To compare medication adherence, persistence and discontinuation
rates tomedications used to treat painful diabetic peripheral neuropathy (PDPN) in
type 2 diabetic patients.METHODS: A retrospective cohort analysis of Texas Med-
icaid prescription claims data of type 2 diabetic patients between 18 and 64 years
whowere on either pregabalin or duloxetine. Datawere extracted from June 2003 to
October 2009. Eligible patients must have been on oral antidiabetic (OAD) medica-
tions at least 6months prior to the index date and have continuous eligibility for at
least 12 months post-index. Cohorts were constructed through propensity scoring
while controlling for baseline differences in demographics and pre-index medica-
tion use. The outcome variables were medication possession ratio (MPR), persis-
tence and discontinuation rates. Sensitivity analyses were conducted for both per-
sistence and discontinuation rates. RESULTS: The two study cohorts included 652
pregabalin and 652 duloxetine patientswith an overallmean age of 51.97.9.Mean
MPR for duloxetine (85.6%  18.2%) was significantly higher compared to pregaba-
lin (68.6% 25.0%); t 14.03; p□ 0.0001. The proportion of adherent patients
(MPR80%) on duloxetine (72.1%) was higher compared to pregabalin (40.2%); X2
134.74; p□0.001. Mean persistence for duloxetine (222.9 days  130.5) was signifi-
cantly longer compared to pregabalin (165.1 days 128.3)when a 60-day gap period
was used; t7.98; p□0.0001. Results of sensitivity analysis using 30, 90 and 120 days
gap periodswere robust. Also, the proportion of patients on duloxetine (65.5%)who
discontinued their medication was lower compared to pregabalin (79.8%) when a
90-day gap period was used (X2 38.94; p□0.0001). Results of sensitivity analysis
using 60 and 120 day gaps were also robust. CONCLUSIONS: Type 2 diabetes pa-
tients on duloxetine had significantly higher medication adherence and persis-
tence with lower discontinuation rates compared to patients on pregabalin.
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THE ECONOMIC IMPACT OF INCREASING THE LEVEL OF DRUG ADHERENCE IN
DIABETIC PATIENTS AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)
Uc-Coyoc R, Arroyave-Loaiza MG, Lara-Gomez JE, Trejo-Amador U,
Rodriguez-Díaz Ponce MA
Instituto Mexicano del Seguro Social, D.F, Mexico
OBJECTIVES: The lack of adherence to diabetic drugsmay reduce the effectiveness
of the treatment increasing the hospitalization rates and costs. The purpose of this
study is to estimate the economic savings derived from comparing different dia-
betic drug adherence scenarios at the Mexican Institute of Social Security (IMSS).
METHODS: For patients with non-complicated diabetes mellitus, 19 pharmacolog-
ical treatment patterns and their distribution were identified by a panel of experts
from primary medical units and general and specialized hospitals. The total pop-
ulation of diabetic patients at IMSS in the year 2010was obtained from the diabetes
census; the percentage of patients under pharmacological treatment came from
the institutional health survey of 2010. Four drug adherence scenarios derived from
institutional studies were considered. All-cause hospitalization rates among dia-
betes drug adherent and non-adherent patients were derived from the interna-
tional literature due to the lack of national estimations. The annual total costs
included the pharmacological and all-cause hospitalization estimates for each
treatment pattern. The exchange rate was $12.34 pesos per dollar. RESULTS: The
metformin-glibenclamide combination was the most prescribed pharmacological
treatment at the Institute (26.6%) followed by metformin-insulin NPH (11.8%) and
metformin (11.2%). The diabetic drug adherence baseline scenario was 16%; this
was compared with three scenarios of 17.2%, 27% and 54.2% respectively. The
annual total costs were 6.05 times greater in non-adherent compared with adher-
ent patients in the baseline scenario. The economic savings increases as the level
of compliance scales up. This can be attributed to the cost reductions compared to
non-adherent patients mainly due to hospitalization. In the year 2010, savings
varied fromUSD$1.48million toUSD$47.01million.CONCLUSIONS:Health policies
that aim to increase adherence to diabetic drugs among patients are needed at the
institution in order to avoid unnecessary costs mainly among non-adherent pa-
tients.
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THE ASSOCIATION BETWEEN NON-ADHERENCE AND HBA1C AMONG TYPE 2
DIABETES PATIENTS USING BASAL INSULIN ANALOGUES
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OBJECTIVES: The aim of the current study was to determine the association be-
tweenmedicationnon-adherence andHbA1c levels among type 2 diabetes patients
currently using basal insulin analogues. METHODS: Data from the 2011 U.S. Na-
tional Health and Wellness Survey (NHWS) were used. The NHWS is a patient-
reported survey fielded to a demographically-representative sample of the adult US
population (N75,000). Analyses were restricted to those who reported a diagnosis
of type 2 diabetes, were currently using insulin glargine or insulin detemir, had
non-missing self-reported HbA1c values, and had non-missing medication adher-
ence data (assessed using the Morisky Medication Adherence Scale (MMAS)). The
association between medication non-adherence and HbA1c was examined using
multiple regressions controlling for sociodemographics, health behaviors, and
comorbidities. RESULTS: A total of 768 patients met the study inclusion criteria.
These patients weremostlymale (64.71%), had amean age of 61.39 (SD9.85), were
predominantly obese (72.92%), and reported a mean HbA1c level of 7.31%
(SD1.41%). A third of patients (33.20%) reported engaging in at least one non-
adherent behavior; the most common was being forgetful with their medication
(28.52%) followed by being careless with their medication (13.02%). Adjusting for
covariates, a higher non-adherence score was significantly associated with in-
creased HbA1c (b0.33, p.0001). When entering all non-adherent behaviors from
theMMAS separately into themodel being careless (b0.44, p.008) was the stron-
gest predictor of increased HbA1c levels. CONCLUSIONS: The results suggest that a
sizeable proportion of T2D patients using basal insulin analogues engage in some
form of non-adherent behavior, the most common being forgetfulness and care-
lessness with the administration of their medication. Even after adjusting for con-
founding variables, the presence of non-adherent behaviors (particularly careless-
ness) was associated with significantly higher levels of HbA1c. Improved
adherence of these patients may result in clinical benefits.
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DIABETES MELLITUS: A LITERATURE REVIEW
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OBJECTIVES: To provide an overview of subjective and objective measures used in
clinical trials to assess adherence or compliance to medical treatment in diabetes
mellitus, to identify trends in the measurement of adherence/compliance, stan-
dardization, and/or tool usage frequency.METHODS:The searchwas performed on
September 1, 2011 and was limited to articles written since 2000. The following
keywords and their descriptors inMedline viaOVIDwere used: patient compliance,
adherence, clinical trials, and diabetes mellitus. Once the abstracts had been re-
trieved, they were carefully reviewed and either selected or rejected, according a
ranking process. RESULTS: A total of 508 references were retrieved and 108 se-
lected. Forty-eight measures were identified: 36 to assess adherence, and 12 to
assess compliance. Among the adherence measures, 27 were subjective measures
such as patient-reported outcome (PRO) instruments and nine, objective. The
most-quoted subjectivemeasures usedwere theDiabetes Self-Management Profile
(DSMP) conventional or flexible regimen versions (four times); the Summary of
Diabetes Self-Care Activities (SDSCA) (four times); the five-itemMedication Adher-
ence Report Scale (MARS-5) (two times); theMoriskyMedication-Taking Adherence
Scale (MMAS) (two times); and the Brief Medication Questionnaire (BMQ) (two
times). Themost-quoted objectivesmeasures to assess adherencewere the refill of
repeat prescriptions (cited six times) and pill cap monitoring systems (five times).
As for the assessment of compliance, only two were subjective measures and ten
were objective. The PROmeasures retrieved were the Chronic Disease Compliance
Instrument and a Medication Compliance Scale. The most frequently used objec-
tivemeasure was the evaluation of return of study drugs. CONCLUSIONS:Diabetes
is a challenging disease to manage successfully and the associated costs of non-
adherence are high. This review shows a lack of standardization/consistency in the
measurement of adherence/compliance in diabetes. More research is needed on
what are the “best” tools to use tomeasure adherence-related behavior in diabetes.
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IMPACT OF ADHERENCE TO ORAL DIABETES MEDICATION ON SHORT-TERM
DISABILITY COSTS IN AN EMPLOYER POPULATION
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OBJECTIVES: The impact of adherence to hypoglycemic agents on the medical/
pharmacy costs of diabetes patients has been examined frequently in the litera-
ture, but the analogous impact on disability costs is not well-documented. This
study assesses the relationships between medication adherence and short-term
disability costs in a large manufacturing company. METHODS: A retrospective
analysis of pharmacy claims was conducted to identify individuals within a large
manufacturing company who were continuously eligible for a three-year time
frame (between 2001 and 2007) and who received a prescription for an oral hypo-
glycemic during that time; in those cases where an individual’s eligibility spanned
a longer time period, the most recent three-year span was chosen. Individuals on
insulin were excluded from the study population. The resulting sample included
both treatment-naïve and treatment-experienced patients, reflective of real-world
employer experience. Medical, pharmacy, and short-term disability costs were cal-
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